Skylar Jeremias

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

Tariff increases threaten the US economy and health care costs, impacting managed care affordability and member financial stability.

A novel blood test offers affordable early detection of Alzheimer disease, enhancing awareness and intervention opportunities during Alzheimer’s and Brain Awareness Month.

Stem cell transplants could produce promising remission rates for children with severe monogenic inflammatory bowel disease (IBD), transforming treatment options.

A novel machine learning model enhances colorectal cancer (CRC) prognosis and immunotherapy response prediction by integrating clinical data and immune gene expression.

Pediatric mental health crises surge as emergency department (ED) waits exceed 12 hours, highlighting urgent needs for systemic health care improvements.

Gastropsychiatrist Eva Szigethy, MD, PhD, and Benjamin Cohen, MD, Cleveland Clinic, discuss quality of life improvement in terms of behavioral health and inflammatory bowel disease (IBD).

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a promising treatment alternative.

The FDA previously approved Jivi in 2018 to treat adults aged 12 years and older with hemophilia A.

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and real-world data, with findings reinforced by new results presented at Digestive Disease Week 2025.

As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.

The American Society for Gastrointestinal Endoscopy has issued new guidelines for diagnosing and managing gastroesophageal reflux disease (GERD), with updated recommendations on endoscopy use, lifestyle changes, and endoscopic treatments like transoral incisionless fundoplication.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.

Long-term exposure to multiple air pollutants may silently wreak havoc on your gut, significantly increasing the risk of gastrointestinal diseases and underscoring the urgent need for public health policies that clean the air we breathe and protect our digestive health.

Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.

Healthy dietary patterns, rich in fruits, vegetables, whole grains, and legumes, may significantly reduce the risk and mortality of gastrointestinal cancers, while diets high in red and processed meats, alcohol, and sugary beverages can increase these risks.

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients aged 2 and older without early treatment.

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in the gastrointestinal (GI) tract, particularly for managing inflammatory bowel disease (IBD).

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual meeting.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration challenges, with key selection factors like patient age and gene copy number, according to Julie Parsons, MD, a professor and neurologist from the University of Colorado School of Medicine.

Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.

Rising biosimilar adoption, shifting market dynamics, and escalating supply chain vulnerabilities are driving change in managed care, creating both challenges and opportunities for stakeholders, as explored by speakers at the Academy of Managed Care Pharmacy’s annual meeting.

As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.

Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.

The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies.